Hepatocyte growth factor for treatment of diabetes

• US 6,472,366 B2
• Filed: 01/25/2002
• Issued: 10/29/2002
• Est. Priority Date: 01/23/1997
• Status: Expired due to Fees

• Current Assignee: Sumitomo Pharmaceuticals Company Limited (Sumitomo Chemical Company Limited)
• Original Assignee: Sumitomo Pharmaceuticals Company Limited (Sumitomo Chemical Company Limited)
• Inventors: Noguchi, Hiroshi, Ichihara, Junji, Taiji, Mutsuo, Kishino, Michiko, Nakayama, Chikao
• Primary Examiner(s): Weber, Jon P.
• Assistant Examiner(s): LEITH, PATRICIA A
• Application Number:
  US10/055,380
• Publication Number:
  US 20020122829A1
• Time in Patent Office: 277 Days
• Field of Search: 424/198.1, 514/2, 514/12, 514/21, 514/4
• US Class Current: 514/9.5
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Abstract

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Claims

1. A method for controlling blood glucose levels in a mammal or patient having non-insulin dependent diabetes mellitus comprising:

administering a therapeutic agent comprising an effective amount of a hepatocyte growth factor to the mammal or patient in need thereof.

3. The method according to claim 1 or 2, wherein the effective amount is 0.01 μ

g/kg to 40 mg/kg by weight of the mammal or patient.

4. The method according to claim 1 or 2, wherein the therapeutic agent is administered subcutaneously, intravenously or intramuscularly.

2. A method for controlling blood lipid levels in a mammal or patient having non-insulin dependent diabetes mellitus comprising:

administering a therapeutic agent comprising an effective amount of a hepatocyte growth factor to the mammal or patient in need thereof.